←
Protagonist Therapeutics694 posts
Protagonist Therapeutics avatar

Protagonist Therapeutics

@ProtagonistTx

Discovering and developing novel therapies through our proprietary peptide technology platform. #biotech #lifesciences #innovation

◷ Joined December 2020▧ 366 Photos and videos
Protagonist Therapeutics avatar
Protagonist Therapeutics@ProtagonistTx·Oct 27

Protagonist Therapeutics will participate in four investment bank conferences this November, with members of our senior management team meeting with investors in New York and London.   • 𝗡𝗼𝘃𝗲𝗺𝗯𝗲𝗿 𝟭𝟬: Wolfe Research Healthcare Conference   • 𝗡𝗼𝘃𝗲𝗺𝗯𝗲𝗿 𝟭𝟮: Truist Securities Biopharma Symposium   • 𝗡𝗼𝘃𝗲𝗺𝗯𝗲𝗿 𝟭𝟲: UBS Global Biopharma Conference   • 𝗡𝗼𝘃𝗲𝗺𝗯𝗲𝗿 𝟭𝟳: Jefferies Global Healthcare Conference A replay of the fireside chats will be available on the Investor Relations Events and Presentations webpage following the events. Learn more: tinyurl.com/2r5hjc8w #ProtagonistTherapeutics #PTGX #Biotech

0:28
Protagonist Therapeutics avatar
Protagonist Therapeutics@ProtagonistTx·Oct 23

Protagonist is very pleased to see another global approval for ICOTYDE™ (icotrokinra)! ICOTYDE, co-discovered by Protagonist and Johnson & Johnson scientists, has now been approved in the United Kingdom for adults and adolescents with moderate-to-severe plaque psoriasis. This latest approval builds on approvals in the U.S., China, and EU, bringing ICOTYDE to more patients around the world. gov.uk/government/news/mhra-… #ICOTYDE #PeptideTherapeutics #PTGX

Post attachment
Protagonist Therapeutics avatar
Protagonist Therapeutics@ProtagonistTx·Oct 16

What a week for Protagonist Therapeutics! Protagonist received three exciting industry recognitions highlighting our innovation and business performance. With two FDA-approved, first-in-class peptidic medicines, #ICOTYDE™ and #MIMRYLO™ and a growing pipeline of differentiated peptide therapeutics, we continue to build on our successes as we advance new treatment options for patients. 🏆 TIME Best Inventions of 2026: ICOTYDE™ (icotrokinra), jointly discovered by Protagonist and Johnson & Johnson, was named one of TIME's Best Inventions of 2026. 🏆 Newsweek's America's Greatest Mid-Market Companies 2026: Protagonist was recognized for its strong business performance and continued growth. 🏆 Fierce Innovation Awards: Protagonist was named a finalist in the Biotech Innovation category of the 2026 Fierce Innovation Awards. Thank you, Fierce Life Sciences Events, for this recognition! #PTGX #FierceInnovator #Biotechnology #Innovation #PeptideTherapeutics

0:05
Protagonist Therapeutics avatar
Protagonist Therapeutics@ProtagonistTx·Oct 15

We are thrilled to share that ICOTYDE® (icotrokinra) has been named one of TIME Magazine's Best Inventions of 2026 in the Medical & Healthcare category! Jointly discovered by Protagonist Therapeutics and Johnson & Johnson scientists, ICOTYDE is the first and only targeted oral peptide therapy that selectively blocks the IL-23 receptor, offering a new oral treatment option for patients with moderate-to-severe plaque psoriasis. This recognition is a testament to the years of dedication, scientific innovation and hard work from the teams at Protagonist and Johnson & Johnson who helped bring ICOTYDE from discovery to patients. Read more: tinyurl.com/TIMEbestinventio… #TIMEBestInventions #ICOTYDE #PeptideInnovation

Post attachment
Protagonist Therapeutics avatar
Protagonist Therapeutics@ProtagonistTx·Oct 13

Protagonist Therapeutics is pleased to announce publication of the primary data from the pivotal Phase 3 VERIFY study of rusfertide in the Journal of Clinical Oncology. These data continue the momentum from the Plenary Presentation at #ASCO25. #PolycythemiaVera patients on rusfertide in the VERIFY study maintained hematocrit control, experienced a reduced phlebotomy burden, and noted improvements in fatigue and other patient reported outcomes. Read the publication: ascopubs.org/doi/10.1200/JCO…

Protagonist Therapeutics avatar
Protagonist Therapeutics@ProtagonistTx·Oct 2

New two-year Phase 3 data for ICOTYDE® (icotrokinra) were presented today by Johnson & Johnson at #EADV2026, supporting ICOTYDE’s potential as a first-line systemic therapy and targeted oral treatment option for patients with difficult-to-treat psoriasis who need to move beyond topical therapy. The Protagonist team is excited to be at EADV celebrating this achievement while connecting with KOLs and investigators about what’s next: advancing our IL-17 antagonist, PN-881, toward a planned Phase 2b psoriasis study in early 2027. Read more: tinyurl.com/6spcd9ac #ICOTYDE #Psoriasis #PeptideTherapeutics

Post attachmentPost attachmentPost attachment
Protagonist Therapeutics avatar
Protagonist Therapeutics@ProtagonistTx·Sep 23

This week, the European Commission approved ICOTYDE™ (icotrokinra) for adults and adolescents with moderate-to-severe plaque psoriasis who are candidates for systemic therapy. Following approvals in the U.S. and China, European approval represents another important step in the global expansion of ICOTYDE — and further demonstrates the potential of targeted oral peptides to become an important new therapeutic option for patients worldwide. ema.europa.eu/en/medicines/h… #ICOTYDE #PeptideTherapeutics #PTGX

Protagonist Therapeutics avatar
Protagonist Therapeutics@ProtagonistTx·Sep 9

With two FDA-approved medicines from our peptide platform in 2026 and a growing pipeline of wholly owned programs, Protagonist is entering an exciting new phase. CEO Dinesh V. Patel is in New York City this week for two investor conferences. Tune in to hear his perspective on what’s next for Protagonist. Citi Biopharma Back to School Conference: Fireside Chat Day/Time: Today, September 9 at 10:40 AM ET Watch the replay: tinyurl.com/35wcj5pw 2026 Cantor Global Healthcare Conference: Fireside Chat Day/Time: Thursday, September 10 at 10:20 AM ET Webcast: tinyurl.com/4uv35drn

0:16
Protagonist Therapeutics avatar
Protagonist Therapeutics@ProtagonistTx·Sep 3

The FDA approval of MIMRYLO™ (rusfertide) shows what strong partnerships make possible. Protagonist CEO Dinesh Patel and EVP of Business Development Carter King reflect on how Protagonist and Takeda brought complementary strengths to a shared goal: bringing a first-in-class new medicine to patients who need it. #PTGX #Biotech #Partnership

1:04
Protagonist Therapeutics avatar
Protagonist Therapeutics@ProtagonistTx·Aug 31

The FDA approval of MIMRYLO™ (rusfertide) marks the culmination of more than a decade of work at Protagonist. Members of our team reflect on the journey and the patients, investigators, partners, and colleagues who helped make it possible. #PTGX #FDAApproval #PV

0:57
Protagonist Therapeutics avatar
Protagonist Therapeutics@ProtagonistTx·Aug 29

Today, we're proud to announce that the U.S. FDA has approved MIMRYLO™ (rusfertide), the first and only hepcidin mimetic peptide therapy approved for the treatment of erythrocytosis in adults with polycythemia vera (#PV), offering a novel mechanism to maintain hematocrit control, meaningfully reduce phlebotomy burden, and improve fatigue. This achievement represents the successful outcome of more than 14 years of scientific innovation and dedication. MIMRYLO marks the second FDA approval after ICOTYDE™ in 2026 for Protagonist. This is a testament to our emerging leadership in peptide therapeutics and our ability to consistently deliver innovative medicines addressing unmet needs for patients. We would like to express our sincere gratitude to the Protagonist employees, our partner Takeda, research collaborators, clinical investigators, and patients who made this defining moment possible. Investor call: Monday, August 31st at 8:30 am ET. Read the full announcement for more details: feeds.issuerdirect.com/news-…

0:31
Protagonist Therapeutics avatar
Protagonist Therapeutics@ProtagonistTx·Aug 28

China’s drug regulator has approved #ICOTYDE for moderate-to-severe plaque psoriasis. ICOTYDE continues to demonstrate the power of our peptide discovery platform and long-term collaboration with Johnson & Johnson. With approvals now in the U.S. and China, we look forward to the European Commission’s decision and the potential to bring this differentiated oral therapy to more patients globally. finance.yahoo.com/healthcare… #Psoriasis #IL23 #OralPeptides

Post attachment
Protagonist Therapeutics avatar
Protagonist Therapeutics@ProtagonistTx·Aug 24

On Friday, @ProtagonistCEO Dinesh Patel joined @SchwabNetwork #NextGenInvesting live to discuss peptides, obesity, and biopharma disruption. Watch it here: schwabnetwork.com/video/prot… #schwabnetwork